Protocol
09-114
Full Title
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Purpose
This study is evaluating an investigational approach that uses immune cells called T cells to kill B-cell acute lymphoblastic leukemia (ALL) that has returned, stopped responding to therapy, or is in first remission and at risk of returning. The T cells are removed from the patient’s blood, modified in a laboratory, and then returned to the patient’s body.
Investigators put a gene in the patient’s T cells that allows them to recognize and kill leukemia cells. The gene will produce a protein in T cells that helps them recognize leukemia cells and possibly kill them. Researchers have found that T cells modified in this way can cure an ALL-like cancer in laboratory studies.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have B-cell ALL that has returned, stopped responding to therapy, or is in first complete remission and at risk of returning.
- Patients’ ALL must be positive for the CD19 antigen.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Renier Brentjens at 212-639-7053.
Disease(s)
Leukemia
Leukemia: Acute Lymphoblastic Leukemia
Locations
ClinicalTrials.gov
Related Diseases
